Literature DB >> 27194777

Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone?

Scott Cherry1, Dan Siskind2, Valeria Spivak3, Daniel Wysoczanski4, Priyangika Halangoda4.   

Abstract

OBJECTIVE: Clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (TRS). However, one potentially lethal side effect of clozapine, as with other antipsychotics, is neuroleptic malignant syndrome (NMS) which could present differently in clozapine therapy. 'Atypical NMS' is a recognised variant of NMS with less rigidity and delayed elevation of creatine kinase; this variant is associated with clozapine.
METHOD: A case from the author's clinical practice was reviewed.
RESULTS: A 67-year-old man with TRS was treated with clozapine. Unfortunately, his physical condition deteriorated and he presented with atypical NMS, which initially was treated as presumable urinary tract infection.
CONCLUSIONS: Atypical NMS is associated with clozapine. This case exposes the potential difficulties in diagnosis, and highlights the importance of considering less common diagnoses in acutely unwell psychiatric patients. © The Royal Australian and New Zealand College of Psychiatrists 2016.

Entities:  

Keywords:  atypical; clozapine; neuroleptic malignant syndrome

Mesh:

Substances:

Year:  2016        PMID: 27194777     DOI: 10.1177/1039856216649768

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  1 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.